DIVISLAB
Divis Laboratories
Each stock's 10,000-path forecast, rendered as light.
Divis Laboratories (DIVISLAB) Stock Analysis & Case Study
Is DIVISLAB a good buy? The data-driven verdict.
Divis Laboratories (DIVISLAB) trades at ₹6,788,on the numbers it mixed signals, a Downstox Snapshot Score of 53/100.
On the numbers, Divis Laboratories (DIVISLAB) mixed signals, a Downstox Snapshot Score of 53/100, weighing expensive at 68.7× earnings, ROE of 16.5%, a 76% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
DIVISLAB fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is DIVISLAB overvalued? DIVISLAB P/E vs its Pharma
DIVISLAB's P/E of 68.7× sits above the Pharma peer median of 30.0×, so on earnings it screens richer than peers, while its 0.44% dividend yield is below the peer median of 0.51%.
DIVISLAB share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of DIVISLAB history (20%/yr drift, 25%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| DIVISLAB 2027 | ₹5,804 | ₹8,031 | ₹11,138 | +19% |
| DIVISLAB 2028 | ₹6,052 | ₹9,530 | ₹15,069 | +41% |
| DIVISLAB 2029 | ₹6,380 | ₹11,252 | ₹19,834 | +67% |
| DIVISLAB 2030 | ₹7,045 | ₹13,493 | ₹25,512 | +100% |
| DIVISLAB 2031 | ₹7,827 | ₹16,050 | ₹32,840 | +138% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability DIVISLAB goes up, or doubles?
The bull case for DIVISLAB
- A healthy 16.5% return on equity.
- Strong ROCE (22.0%) shows the core business earns well above its cost of capital.
- A 10,000-path probability model puts a 76% chance the price is higher in a year, with a median target of ₹8,031 (+19%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹19,834.
The bear case & risks
- A rich 68.7× P/E leaves a thin margin of safety if growth slows.
- A steep 10.8× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹6,380.
DIVISLAB volatility & expected range, how bumpy is the ride?
Over the last 2.0 years DIVISLAB compounded at 20%/year with annualized volatility of 25%. That volatility implies a 1-year 80% range of ₹5,804–₹11,138, the honest backbone behind any single price target.
DIVISLAB price forecast, the full 60-month probability fan
DIVISLAB price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds DIVISLAB hits common targets within the simulated horizon?
Full multi-horizon detail on the DIVISLAB price target & forecast page.
DIVISLAB Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. DIVISLAB scores 4/9,mixed financial health.
DIVISLAB MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy DIVISLAB with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 26.9% | 3.7× |
| Zerodha | 23.0% | 4.3× |
| DhanCHEAPEST | 22.0% | 4.5× |
Compare every broker on the DIVISLAB MTF page.
DIVISLAB vs peers,Pharma comparison
About Divis Laboratories: sector, index & market-cap context
Divis Laboratories (DIVISLAB) is a large-cap NSE-listed company in the Pharma sector, and a constituent of the Nifty 50 index group, with a market capitalisation of ₹1.80L Cr. See more Nifty 50 stocks.
How the DIVISLAB Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Divis Laboratories's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
DIVISLAB analysis, FAQs
Is Divis Laboratories (DIVISLAB) a good buy?
On the numbers, Divis Laboratories (DIVISLAB) mixed signals, a Downstox Snapshot Score of 53/100, weighing expensive at 68.7× earnings, ROE of 16.5%, a 76% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is DIVISLAB overvalued or undervalued?
DIVISLAB trades at 68.7× earnings versus a peer median of 30.0×, so it screens richer than its Pharma peers.
What is the DIVISLAB share price target for 2031?
DIVISLAB's probability-weighted 2031 median target is ₹16,050, with an 80% range of ₹7,827–₹32,840 (10,000-path Monte-Carlo).
What is the probability DIVISLAB doubles in 5 years?
The modelled probability of DIVISLAB reaching ₹13,486 (2×) within 5 years is 62%.
What is the bull case for DIVISLAB?
A healthy 16.5% return on equity. Strong ROCE (22.0%) shows the core business earns well above its cost of capital. A 10,000-path probability model puts a 76% chance the price is higher in a year, with a median target of ₹8,031 (+19%).
What are the risks in DIVISLAB?
A rich 68.7× P/E leaves a thin margin of safety if growth slows. A steep 10.8× price-to-book means most of the value is intangible/expectations, not assets on the books.